Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies

Cancer Immunology, Immunotherapy

Volumn 67, Issue 12, 2018, Pages 1833-1844

  Dobry, Allison S ^a,b   Zogg, Cheryl K ^c,d   Hodi, F Stephen ^a,e   Smith, Timothy R ^a,c   Ott, Patrick A ^a,e   Iorgulescu, J Bryan ^a,c,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Immune checkpoint blockade; Immunotherapy; Melanoma; Metastasis; Targeted therapy

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC MONOCLONAL ANTIBODY; B RAF KINASE INHIBITOR; DABRAFENIB; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; B RAF KINASE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CUTANEOUS MELANOMA; DRUG APPROVAL; DRUG MEGADOSE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; KAPLAN MEIER METHOD; LOCAL EXCISION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY; WIDE EXCISION; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CANCER STAGING; COMORBIDITY; DISEASE MANAGEMENT; GENETICS; HEALTH CARE SURVEY; IMMUNOTHERAPY; METABOLISM; MORTALITY; ODDS RATIO; REGISTER; SYMPTOM ASSESSMENT; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; COMORBIDITY; DISEASE MANAGEMENT; FEMALE; HEALTH CARE SURVEYS; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; ODDS RATIO; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; REGISTRIES; SYMPTOM ASSESSMENT; UNITED STATES; YOUNG ADULT;

EID: 85053461232     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-018-2241-x     Document Type: Article

References (35)

1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. 10.3322/caac.21332
2. Glazer AM, Winkelmann RR, Farberg AS, Rigel DS (2017) Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol 153:225–226. 10.1001/jamadermatol.2016.4512
3. Eggermont AM, Spatz A, Robert C (2014) Cutaneous melanoma. Lancet 383:816–827. 10.1016/S0140-6736(13)60802-8
4. Force J, Salama AK (2017) First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Ther 6:1–10. 10.2147/ITT.S110479
5. Ascierto PA, McArthur GA, Dréno B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248–1260. 10.1016/S1470-2045(16)30122-X
6. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707–714. 10.1056/NEJMoa1112302
7. Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19:603–615. 10.1016/S1470-2045(18)30142-6
8. Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309. 10.1158/1078-0432.CCR-13-0143
9. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. 10.1056/NEJMoa1003466
10. Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155–164. 10.1016/S1470-2045(09)70334-1
11. Ascierto PA, Del Vecchio M, Robert C et al (2017) Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18:611–622. 10.1016/S1470-2045(17)30231-0
12. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. 10.1056/NEJMoa1503093
13. Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017. 10.1056/NEJMoa1414428
14. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. 10.1056/NEJMoa1504030
15. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356. 10.1056/NEJMoa1709684
16. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. 10.1056/NEJMoa1103782
17. Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444–451. 10.1016/S0140-6736(15)60898-4
18. Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877–1888. 10.1056/NEJMoa1406037
19. Larkin J, Ascierto PA, Dréno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876. 10.1056/NEJMoa1408868
20. Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39. 10.1056/NEJMoa1412690
21. National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology: Melanoma version 2.2018. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#melanoma. Accessed 1 Mar 2018
22. Larkin J, Lao CD, Urba WJ et al (2015) Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 1:433–440. 10.1001/jamaoncol.2015.1184
23. Atkins MB, Larkin J (2016) Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst 108:414. 10.1093/jnci/djv414
24. Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918. 10.1016/S1470-2045(15)00083-2
25. Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384. 10.1016/S1470-2045(15)70076-8
26. Weber JS, Gibney G, Sullivan RJ et al (2016) Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17:943–955. 10.1016/S1470-2045(16)30126-7
27. Hodi FS, Chesney J, Pavlick AC et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558–1568. 10.1016/S1470-2045(16)30366-7
28. Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S (2017) Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev 54:34–42. 10.1016/j.ctrv.2017.01.006
29. Boffa DJ, Rosen JE, Mallin K et al (2017) Using the national cancer database for outcomes research: a review. JAMA Oncol 3:1722–1728. 10.1001/jamaoncol.2016.6905
30. LeBoit PE, Burg G, Weedon D, Sarasain A (2006) Pathology and genetics of skin tumours, 3rd edn. IARC Press, Lyon
31. Iorgulescu JB, Harary M, Zogg CK et al (2018) Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res 6:1–7. 10.1158/2326-6066.CIR-18-0067
32. Shaikh WR, Dusza SW, Weinstock MA et al (2016) Melanoma thickness and survival trends in the United States, 1989–2009. J Natl Cancer Inst 108:1. 10.1093/jnci/djv294
33. Howard JH, Thompson JF, Mozzillo N et al (2012) Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 19:2547–2555. 10.1245/s10434-012-2398-z
34. Barker CA, Postow MA (2014) Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986–997. 10.1016/j.ijrobp.2013.08.035
35. Joosse A, de Vries E, Eckel R et al (2011) Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Investig Dermatol 131:719–726. 10.1038/jid.2010.354